FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285046230> ?p ?o ?g. }

• W4285046230 endingPage "106918" @default.
• W4285046230 startingPage "106918" @default.
• W4285046230 abstract "In the evolution of haploidentical hematopoietic stem cell transplantation (haplo-HSCT), In vivo T-cell modulation with concomitant use of anti-thymocyte globulin (ATG) and high-dose post-transplant cyclophosphamide (PTCy) provides a novel promising method on transplant outcomes; however, the long-term effects of this therapy are mostly unknown. We retrospectively compared the long-term outcomes of adult acute myeloid leukemia (AML) patients undergoing a haplo-HSCT (n = 92) with a new modified combination of ATG and PTCy in the context of peripheral blood stem cell (PBSC) and myeloablative conditioning (MAC) with an otherwise similar group of AML patients who received an unrelated donor (URD) HSCT (n = 57) with ATG protocol from February 2010 to December 2020 at our single-center (HORCSCT). Median follow-up was 3.73 and 4.28 years for haploidentical and URD-HSCT, respectively. In haplo-HSCT, the cumulative incidence of grades II-IV and III-IV acute graft versus host disease (aGvHD) and extensive chronic GvHD (cGvHD) was much lower than in URD (27% versus 56% for grades II-IV, 8.7% versus 24.5% for grades III-IV, and 15.4% versus 34.7% for extensive cGvHD, respectively). Five-year overall survival (OS) was 54.03% for haplo and 54.48% for URD (p = 0.927); GvHD-free relapse-free survival (GRFS) was 44.1% and 29.86% (p = 0.149); relapse incidence was 15.79% and 26.95% (p = 0.72); and non-relapse mortality (NRM) was 29.48% and 26.32% (p = 0.73), respectively. Using multivariable analyses, when compared to Haplo, URD was a significant predictor of relapse (HR=1.80, p = 0.039); however, no difference in OS, GRFS, and NRM was noted between haplo and URD. Therefore, given the favorable results with haplo-HSCT and considering donor availability promptly with low cost, it conservatively suggested that haplo-HSCT with the introduced protocol could be viewed as the first alternative for patients with AML in the absence of matched sibling donors." @default.
• W4285046230 created "2022-07-13" @default.
• W4285046230 creator A5003719729 @default.
• W4285046230 creator A5030001516 @default.
• W4285046230 creator A5065799539 @default.
• W4285046230 creator A5080856581 @default.
• W4285046230 creator A5084434131 @default.
• W4285046230 creator A5084511527 @default.
• W4285046230 creator A5086980259 @default.
• W4285046230 creator A5090825807 @default.
• W4285046230 creator A5090959902 @default.
• W4285046230 date "2022-09-01" @default.
• W4285046230 modified "2023-09-28" @default.
• W4285046230 title "Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience" @default.
• W4285046230 cites W1536174937 @default.
• W4285046230 cites W2020725971 @default.
• W4285046230 cites W2034544947 @default.
• W4285046230 cites W2038981426 @default.
• W4285046230 cites W2044467556 @default.
• W4285046230 cites W2053278212 @default.
• W4285046230 cites W2059860297 @default.
• W4285046230 cites W2064085613 @default.
• W4285046230 cites W2073140442 @default.
• W4285046230 cites W2086232358 @default.
• W4285046230 cites W2116483603 @default.
• W4285046230 cites W2116858301 @default.
• W4285046230 cites W2126724696 @default.
• W4285046230 cites W2141696179 @default.
• W4285046230 cites W2142493118 @default.
• W4285046230 cites W2142800729 @default.
• W4285046230 cites W2166247867 @default.
• W4285046230 cites W2219528388 @default.
• W4285046230 cites W2287947195 @default.
• W4285046230 cites W2398438055 @default.
• W4285046230 cites W2404301843 @default.
• W4285046230 cites W2560672989 @default.
• W4285046230 cites W2595261904 @default.
• W4285046230 cites W2617449083 @default.
• W4285046230 cites W2618073389 @default.
• W4285046230 cites W2681369214 @default.
• W4285046230 cites W2751829001 @default.
• W4285046230 cites W2766752961 @default.
• W4285046230 cites W2788411229 @default.
• W4285046230 cites W2898523261 @default.
• W4285046230 cites W2965611898 @default.
• W4285046230 cites W2982446134 @default.
• W4285046230 cites W3001557001 @default.
• W4285046230 cites W3004720827 @default.
• W4285046230 cites W3019553493 @default.
• W4285046230 cites W3093198142 @default.
• W4285046230 cites W3110510218 @default.
• W4285046230 cites W4293241248 @default.
• W4285046230 doi "https://doi.org/10.1016/j.leukres.2022.106918" @default.
• W4285046230 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35843087" @default.
• W4285046230 hasPublicationYear "2022" @default.
• W4285046230 type Work @default.
• W4285046230 citedByCount "3" @default.
• W4285046230 countsByYear W42850462302023 @default.
• W4285046230 crossrefType "journal-article" @default.
• W4285046230 hasAuthorship W4285046230A5003719729 @default.
• W4285046230 hasAuthorship W4285046230A5030001516 @default.
• W4285046230 hasAuthorship W4285046230A5065799539 @default.
• W4285046230 hasAuthorship W4285046230A5080856581 @default.
• W4285046230 hasAuthorship W4285046230A5084434131 @default.
• W4285046230 hasAuthorship W4285046230A5084511527 @default.
• W4285046230 hasAuthorship W4285046230A5086980259 @default.
• W4285046230 hasAuthorship W4285046230A5090825807 @default.
• W4285046230 hasAuthorship W4285046230A5090959902 @default.
• W4285046230 hasConcept C126322002 @default.
• W4285046230 hasConcept C143998085 @default.
• W4285046230 hasConcept C151730666 @default.
• W4285046230 hasConcept C203014093 @default.
• W4285046230 hasConcept C2776694085 @default.
• W4285046230 hasConcept C2776755627 @default.
• W4285046230 hasConcept C2777408962 @default.
• W4285046230 hasConcept C2778729363 @default.
• W4285046230 hasConcept C2779343474 @default.
• W4285046230 hasConcept C2779972918 @default.
• W4285046230 hasConcept C2780882860 @default.
• W4285046230 hasConcept C2911091166 @default.
• W4285046230 hasConcept C71924100 @default.
• W4285046230 hasConcept C86803240 @default.
• W4285046230 hasConcept C88879693 @default.
• W4285046230 hasConcept C90924648 @default.
• W4285046230 hasConceptScore W4285046230C126322002 @default.
• W4285046230 hasConceptScore W4285046230C143998085 @default.
• W4285046230 hasConceptScore W4285046230C151730666 @default.
• W4285046230 hasConceptScore W4285046230C203014093 @default.
• W4285046230 hasConceptScore W4285046230C2776694085 @default.
• W4285046230 hasConceptScore W4285046230C2776755627 @default.
• W4285046230 hasConceptScore W4285046230C2777408962 @default.
• W4285046230 hasConceptScore W4285046230C2778729363 @default.
• W4285046230 hasConceptScore W4285046230C2779343474 @default.
• W4285046230 hasConceptScore W4285046230C2779972918 @default.
• W4285046230 hasConceptScore W4285046230C2780882860 @default.
• W4285046230 hasConceptScore W4285046230C2911091166 @default.
• W4285046230 hasConceptScore W4285046230C71924100 @default.
• W4285046230 hasConceptScore W4285046230C86803240 @default.

• next